The primary endpoint was met, with 57% of subjects treated with the therapy achieving clear or almost clear skin.

Icotrokinra demonstrated high rates of clearance in scalp and genital psoriasis after 16 weeks of treatment, according to ...

Guselkumab treatment was associated with improvements in 3 biomarkers associated with systemic inflammation among patients with plaque psoriasis.

Pronounced “soh-TIK-too,” SOTYKTU is a once-daily pill for adults with moderate to severe plaque psoriasis that works inside ...

Icotrokinra led to high rates of skin clearance in patients with scalp and genital psoriasis, according to results from the ICONIC-TOTAL study.

Johnson & Johnson (J&J) and Protagonist Therapeutics’ investigational oral peptide icotrokinra (JNJ-2113) has been associated ...

J&J JNJ announced positive data from the phase III ICONIC-TOTAL study evaluating its investigational oral peptide, ...

Selardsdi is indicated for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis in adults and ...

The biosimilar SYSA1902 is similar to reference ustekinumab for both efficacy and safety measures among patients with plaque psoriasis.

Phase 3 trial results released by Protagonist Therapeutics has revealed that icotrokinra, an oral IL-23 receptor inhibitor, achieved clear or nearly clear skin in 66% of patients with ...

House: Johnson & Johnson has announced new data from the Phase 3 ICONIC-TOTAL study investigating icotrokinra (JNJ-2113), the ...